|
Real-world treatment patterns in von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC): Costs of tumor reduction procedures and their complications. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Merck (Inst) |
|
|
Research Funding - Merck (Inst) |
|
|
Research Funding - Merck (Inst) |
|
|
Research Funding - Merck (Inst) |
|
|
Research Funding - Merck (Inst) |
|
|
Consulting or Advisory Role - aravive; Aveo; Calithera Biosciences; Eisai; Exelixis; Merck; NiKang Therapeutics; Novartis; Pfizer; Takeda |
Research Funding - Arrowhead Pharmaceuticals (Inst); Merck; NiKang Therapeutics; Novartis |
Travel, Accommodations, Expenses - Pfizer |